66th ASH Annual Meeting: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster III

Symposia: Myelodysplastic Syndromes: Clinical and Epidemiological Oral and Poster Abstracts
Poster

Research, Acute Myeloid Malignancies, Combination therapy, AML, MDS, Clinical trials, Adult, Clinical Practice (Health Services and Quality), Drug development, APL, MPN, Translational Research, Epidemiology, Elderly, Genetic Disorders, Genomics, Chemotherapy, CML, Clinical Research, Health outcomes research, Hematopoiesis, Chronic Myeloid Malignancies, CMML, Education, Diseases, Immune mechanism, Therapy sequence, Patient-reported outcomes, Treatment Considerations, Real-world evidence, Adverse Events, Non-Biological therapies, Registries, Biological Processes, Myeloid Malignancies, Survivorship, Technology and Procedures, Molecular biology, Study Population, Human, Pathogenesis, Molecular testing

Halls G-H (San Diego Convention Center)

4579

Incorporating TET2 Variant Allele Frequency Enhances Prognostication in CMML: Insights from 849 Patients across Multiple Institutions

Yu-Hung Wang, MD^1,2^*, Dorothée Selimoglu-Buet, PhD³^*, Carmelo Gurnari, MD, PhD⁴, Andres Jerez, MD, PhD⁵^*, Andrius Zucenka, MD^6,7, Chi-Yuan Yao, MD⁸^*, Chien-Chin Lin, MD, PhD⁸^*, Hsin-An Hou, M.D.; Ph.D.², Wen-Chien Chou, MD, PhD⁸, Hwei-Fang Tien, MD, PhD⁹, Jaroslaw Maciejewski¹⁰, Eric Solary, MD¹¹^*, Kiran Batta, PhD¹² and Daniel H Wiseman, MB ChB PhD¹²^*

¹Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom
²Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
³Université Paris-Sud, Villejuif, FRA
⁴Cleveland Clinic Foundation, Cleveland, OH
⁵Hospital Morales Meseguer, Murcia, Murcia, ESP
⁶Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
⁷Hematology and Oncology Department, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
⁸Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan
⁹Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
¹⁰Taussig Cancer Center, Cleveland, OH
¹¹Inserm UMR866, Villejuif Cedex, France
¹²Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom

4580

Dual Bclxl and BCL2 Inhibition with Navitoclax (NAV), Venetoclax (VEN), and Decitabine (DEC) for Advanced Myeloid Neoplasms (MN): Safety and Biological Activity in a Phase 1 Study

Evan C. Chen, MD¹, Yiwen Liu, MS²^*, Hayden L. Bell, PhD³^*, Ilene A. Galinsky, MSN, ANP-C¹, Marlise R. Luskin, MD¹, Eric S. Winer, MD¹, Maximilian Stahl, MD⁴, Rahul Vedula, MD⁵, Virginia O. Volpe, MD¹, Daniel J. DeAngelo, MD, PhD¹, Karen Quillen, MD, MPH⁶, Jeremy Ryan, MS³^*, Emma-Jayne Minihane, PhD³^*, Matthew Hersch, BA³^*, Rebecca Leonard¹^*, Donna S. Neuberg, ScD⁷, Richard M. Stone, MD⁸, Anthony G. Letai³, Andrew A. Lane, MD, PhD¹ and Jacqueline S. Garcia, MD¹

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
²Data Science, Dana-Farber Cancer Institute, Boston, MA
³Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁴Dana Farber Cancer Institute, Boston, MA
⁵Medical Oncology, Dana-Farber Cancer Institute, Stoneham, MA
⁶Beth Israel Deaconess Medical Center, Boston, MA
⁷Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
⁸Dana-Farber Cancer Institute, Boston, MA

4581

Exploring the Unseen Effects of Epigenetic Age Acceleration in Low-Risk MDS: Associations with Unique Cytokine Profiles

Sven De Pourcq, MSc^1,2^*, Elena Tofacchi, MSc^2,3^*, Marco Gabriele Raddi, MD³^*, Giorgio Mattiuz, PhD³^*, Luca Rigodanza, MD³^*, Angela Consagra, MD³^* and Valeria Santini, MD⁴

¹MDS Unit, Department of Experimental and Clinical Medicine, University of Florence, Firenze, Italy
²Department of Medical Biotechnologies, University of Siena, Siena, Italy
³MDS Unit, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
⁴MDS Unit, Hematology, DMSC, AOU Careggi, University of Florence, Florence, Italy

4582

ETV6 Mutations in Myeloid Neoplasia: Unraveling Clinical Features and Molecular Signatures

Tariq Kewan, MD¹, Luisa Ladel, MD²^*, Ahmad Kiwan, MD¹ and Lourdes M Mendez, MD, PhD³^*

¹Department of Internal Medicine, Section of Hematology, Yale University, New Haven, CT
²Yale University, New Haven, CT
³Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT

4583

Improvement in Quality of Life in MDS Patients Who Become Transfusion Independent after Treatment

Bo Wan, MD¹, Shabbir MH Alibhai, MD, MSc²^*, Lisa Chodirker, MD FRCPC³^*, Lee Mozessohn, MD⁴, Michelle Geddes, MD⁵, Nancy Zhu, MD, FRCPC⁶^*, Amy Trottier, MD, MSc, FRCPC⁷, Eve St-Hilaire, MD, FRCP⁸^*, Nicholas Finn, BSc, MD⁹^*, Brian Leber, MD¹⁰, Dina Khalaf, MSc, MBBS¹¹, Grace Christou, MD, MSc, FRCPC¹²^*, Mitchell Sabloff, MSc, MD, FRCPC¹³, Heather A Leitch, MD, PhD¹⁴, April Shamy, MD¹⁵, Karen Yee, MD, FRCPC¹⁶^*, John M. Storring, MDCM, FRCPC¹⁷, Thomas J. Nevill, MD, FRCPC¹⁸, Brett L. Houston, MD, PhD¹⁹, Mohamed Elemary, MD, MSc, PhD²⁰^*, Robert Delage, MD, MSc²¹, Anne Parmentier, BA²²^*, Mohammad Siddiqui²³^*, Alexandre Mamedov, PhD⁴^*, Liying Zhang, PhD⁴^* and Rena Buckstein, MD, FRCPC³

¹University of British Columbia, Vancouver, BC, Canada
²Department of Supportive Care, Princess Margaret Cancer Centre - University Health Network, Toronto, Canada
³Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
⁴Sunnybrook Health Sciences Centre, Toronto, ON, Canada
⁵Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada
⁶Clinical Assistant Professor Division of Hematology, Department of Medicine, University of Alberta, Edmonton, AB, Canada
⁷Hematology, Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada
⁸Hematology/Oncology, Dr. Georges-L-Dumont University Centre, Moncton, NB, CAN
⁹Hematology/oncology, Dr. Georges-L-Dumont University Centre, Moncton, CAN
¹⁰Division of Hematology, Juravinski Cancer Center, Hamilton, ON, Canada
¹¹Department of Oncology, McMaster University, Hamilton, ON, Canada
¹²Division of Hematology, The Ottawa Hospital, Ottawa, ON, Canada
¹³Ottawa Hospital Research Institute, Ottawa, ON, Canada
¹⁴Hematology, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada
¹⁵Jewish General Hospital, McGill University, Montreal, QC, CAN
¹⁶Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
¹⁷McGill University Health Centre, Montreal, QC, Canada
¹⁸Division of Hematology, Department of Medicine, University of British Columbia, Vancouver, Canada
¹⁹University of Manitoba, Winnipeg, MB, CAN
²⁰Provincial Hematology and Blood and Marrow Transplant Program, Saskatchewan Cancer Agency, University of Saskatchewan, Saskatoon, SK, Canada
²¹Quebec CML-MPN Research Group, Montreal, QC, Canada
²²Sunnybrook Health Sciences, Odette Cancer Center, Toronto, ON, Canada
²³Hematology Clinical Trials, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada

4584

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis

Kelly S. Chien, MD¹, Ziyi Li, PhD²^*, Luca Lanino, MD³, Najla H. Al Ali, Ms⁴^*, Samuel Urrutia, MD⁵, Rashmi Kanagal-Shamanna, MD⁶, Ahmed Abdelhakeem, MD¹^*, Tareq Abuasab, MD¹^*, Emmanuel Almanza, MD¹^*, Georgina Gener-Ricos, MD¹^*, Alex Bataller, MD, PhD¹^*, Alexandre Bazinet, MD¹^*, Alessia Campagna, MD⁷^*, Giulia Maggioni, MD⁷^*, Eric Padron, MD⁸, Zhuoer Xie, MD, MS⁸, Guillermo Montalban-Bravo, MD¹, Nicholas J. Short, MD¹, Elias Jabbour, MD¹, Tapan M. Kadia, MD¹, Farhad Ravandi, MBBS⁹, Gautam Borthakur, MD¹⁰, Danielle Hammond, MD¹, Mahesh Swaminathan, MD¹, Koji Sasaki, MD¹, Xiao Qin Dong¹^*, Sherry Pierce, BSN, BA¹^*, David Sallman, MD⁸, Hagop M. Kantarjian, MD¹, Matteo Giovanni Della Porta, MD⁷^*, Guillermo Garcia-Manero, MD¹ and Rami S. Komrokji, MD⁸

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
³IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy
⁴Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
⁵Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
⁶Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
⁷IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
⁸Department of Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, FL
⁹Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX
¹⁰Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

4585

Immune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab

Jan Philipp Bewersdorf, MD¹, Vanessa Hasle²^*, Rory M. Shallis, MD³, Ethan G. Thompson, PhD²^*, Daniel Lopes De Menezes, PhD⁴^*, Shelonitda Rose², Isaac W. Boss²^*, Lourdes Mendez, MD⁵^*, Nikolai A. Podoltsev, MD, PhD⁶, Maximilian Stahl, MD⁷, Tariq Kewan, MD⁸, Stephanie Halene, MD⁹, Torsten Haferlach, MD¹⁰, Brian Fox²^* and Amer M. Zeidan, MBBS, MHS¹¹

¹Department of Medicine, Section of Hematology, Yale University, New Haven, CT
²Bristol Myers Squibb, Princeton, NJ
³Department of Internal Medicine, Section of Hematology, Yale School of Medicine - Yale Cancer Center, Killingworth, CT
⁴Translational Medicine, Hematology, Bristol Myers Squibb, San Francisco, CA
⁵Department of Internal Medicine, Section of Hematology, Yale School of Medicine - Yale Cancer Center, New Haven, CT
⁶Department of Internal Medicine, Section of Hematology, Yale University School of Medicine and Yale Cancer Center, Madison, CT
⁷Dana Farber Cancer Institute, Boston, MA
⁸Department of Internal Medicine, Section of Hematology, Yale University, New Haven, CT
⁹Department of Internal Medicine, Section of Hematology, Yale University School of Medicine and Yale Cancer Center, New Haven, CT
¹⁰MLL Munich Leukemia Laboratory, Munich, Germany
¹¹Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT

4586

PHF6 Mutation in Chronic Myelomonocytic Leukemia Is Associated with Chronic Thrombocytopenia and Predicts Superior Overall and Leukemia-Free Survival

Saubia Fathima, MD¹, Ali Alsugair, MBBS², Anuya A. Natu¹^*, Clifford M. Csizmar, MD, PhD³, Mark Gurney, MB, BCh, BAO⁴^*, Terra L. Lasho, PhD¹, Christy Finke, BS⁴^*, Abhishek A. Mangaonkar, MBBS¹, Kaaren K. Reichard, MD⁵, Rong He, MD⁶, Animesh D. Pardanani, MBBS, PhD³, Naseema Gangat, MBBS⁴, Mrinal M. Patnaik, MD, MBBS¹ and Ayalew Tefferi, MD⁴

¹Mayo Clinic, Rochester, MN
²Department of Hematology, Mayo Clinic, Rochester, MN
³Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
⁴Division of Hematology, Mayo Clinic, Rochester, MN
⁵Department of Pathology, Mayo Clinic, Rochester, MN
⁶Division of Hematopathology, Mayo Clinic, Rochester, MN

4587

Characteristics of Myelodysplastic Syndromes with Idiopathic Pulmonary Fibrosis

Ines Zugasti^1,2^*, Samuel Urrutia^3,4^*, Eduardo Edelman Saul, MD⁴, Georgina Daher-Reyes⁵^*, Mohammed Asim Amjad⁶^*, Jia Wu⁷^*, Koji Sasaki, MD⁸, Ajay Sheshadri⁶^* and Guillermo Garcia-Manero, MD⁸

¹GESMD (Grupo Español de Sindromes Mielodisplasicos), Madrid, Spain
²Hematology Department, Hospital Clinic de Barcelona, ICMHO, Barcelona, Spain
³Division of Oncology, Washington University School of Medicine in St. Lous, Saint Louis
⁴Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
⁵Princes Margaret Cancer Center, Toronto, ON, CAN
⁶Department of Pulmonary Medicine, Division of Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
⁷Department of Imaging Physics, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX
⁸Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

4588

Molecular Taxonomic Features of MDS/CMML Patients Influence Response to Hypomethylating Agent Therapy and Clinical Outcomes

Alfonso Molina, MD, MPH¹, Vishesh Khanna, MD², Rong Lu, Phd³^*, Henning Stehr, PhD⁴^*, Brent Tan, MD, PhD⁴^* and Peter L. Greenberg, MD⁵

¹Department of Medicine, Division of Hematology, Stanford University School of Medicine, San Carlos, CA
²Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, CA
³Department of Medicine, Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, CA
⁴Department of Pathology, Stanford University School of Medicine, Stanford, CA
⁵Stanford Cancer Center, Stanford, CA

4589

The Argument for Targeted Therapy in IDH1 Mutated Myelodysplastic Syndromes (MDS): Poor Outcomes Post-Hypomethylating Agent Failure in Higher Risk MDS and Reduced Leukemia Free Survival in Lower Risk MDS

Ziad Abuhelwa, MD, MPH^1,2, Najla H. Al Ali, Ms³^*, Zhuoer Xie, MD, MS⁴, Onyee Chan, MD², Seongseok Yun, MD, PhD³, Andrew T. Kuykendall, MD³, Alison R. Walker, MD, MBA, MPH⁵, Jeffrey E Lancet, MD³, Eric Padron, MD³, David Sallman, MD³ and Rami S. Komrokji, MD³

¹Morsani College of Medicine, University of South Florida, Tampa, FL
²H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
³Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
⁴Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL
⁵Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Wesley Chapel, FL

4590

Initial Results from the QTc Substudy of the IMerge Phase 3 Trial Demonstrate Clinically Meaningful Efficacy, Manageable Safety, and Absence of Proarrhythmic Risk in Patients with Lower-Risk Myelodysplastic Syndromes Who Received Prior Therapies Beyond Erythropoiesis Stimulating Agents

Rami S. Komrokji, MD¹, Valeria Santini, MD², Uwe Platzbecker, MD³, Koen Van Eygen, MD⁴, Maria Diez-Campelo, MD, PhD⁵^*, Raquel De Paz, MD, PhD⁶^*, Guillermo Sanz, MD, PhD^7,8,9, Sylvain Thépot, MD¹⁰^*, Maciej Kaźmierczak, MD, PhD¹¹^*, Esther Natalie Oliva, MD¹², Mikkael A. Sekeres, MD¹³, Pierre Fenaux, MD¹⁴, Yazan F. Madanat, MD¹⁵, Michael R. Savona, MD¹⁶, Jennifer Riggs, MPH¹⁷^*, Souria Dougherty, MBA¹⁷^*, Ashley Lennox, PhD¹⁷^*, Qi Xia, PhD¹⁷^*, Libo Sun, PhD¹⁷^*, Tymara Berry, MD¹⁷^* and Amer M. Zeidan, MD¹⁸

¹Moffitt Cancer Center, Tampa, FL
²MDS Unit, Hematology, AOUC, University of Florence, Florence, Italy
³Department for Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University of Leipzig Medical Center, Leipzig, Germany
⁴AZ Groeninge, Kortrijk, Belgium
⁵Hospital Clínico Universitario de Salamanca, Salamanca, Spain
⁶Servicio de Hematología y Hemoterapia, Hospital Universitario La Paz, Madrid, Spain
⁷CIBERONC, ISCIII, Madrid, Spain
⁸Health Research Institute La Fe, Valencia, Spain
⁹Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain
¹⁰Centre Hospitalier Universitaire d'Angers, Angers, France
¹¹Poznań University of Medical Sciences, Poznań, Poland
¹²Hematology Unit, Grande Ospedale Metropolitano BMM, Reggio Calabria, Reggio Calabria, Italy
¹³Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL
¹⁴Hôpital Saint-Louis, Université de Paris 7, Paris, France
¹⁵Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX
¹⁶Vanderbilt University Medical Center, Nashville, TN
¹⁷Geron Corporation, Foster City, CA
¹⁸Yale School of Medicine, Smilow Cancer Hospital at Yale New Haven, New Haven, CT

4591

Hematologic Improvement and Fatigue Reduction with Elritercept (KER-050) in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS) with Non-Transfusion Dependent Anemia: New Analyses from an Ongoing Phase 2 Trial

Shuhying Tan, FRACP, FRCPA, MBBS¹^*, Montserrat Arnan, MD, PhD²^*, Lynette C.Y. Chee, MBBS, PhD, FRACP, FRCPA³, Thomas Cluzeau, MD, PhD⁴, Maria Diez-Campelo, MD, PhD⁵^*, Aristoteles Giagounidis, MD⁶, Devendra Hiwase, MD, MBBS, PhD, FRACP, FRCPA⁷, David M Ross, MD, PhD, FRACP, FRCPA⁸^*, Mikkael A. Sekeres, MD⁹, David Valcarcel, MD, PhD¹⁰, Bhavna Patel-Shah¹¹^*, Ming Yang, PhD¹¹^*, Ying Jiang, PhD, MBA¹¹^*, Jiani Yin, PhD¹¹^*, Suresh Bobba¹¹^*, Montagu Hankin, MSc¹¹^*, Chris Materna, MSc¹¹^*, Christine Graham, PhD¹¹^*, Sanjay Thamake, PhD, MBA¹¹^*, Christopher Rovaldi, MSc¹¹^*, Dena Grayson, MD, PhD¹¹^* and Jen L. Salstrom, MD, PhD¹¹

¹St. Vincent's Institute of Medical Research, East Melbourne, Vic, AUS
²Hematology Department. Institut Català d’Oncologia, Hospital Duran i Reynals. Institut d’Investigació Biomèdica de Bellvitge (IDIBELL). Universitat de Barcelona, Hospitalet de Llobregat, Barcelona, Spain
³Department of Clinical Haematology and Bone Marrow Transplant Service, The Royal Melbourne Hospital, Parkville, Australia
⁴Department for Clinical Hematology, Nice University Hospital, Nice, Provence Alpes Cote d'Azur, France
⁵Hospital Clínico Universitario de Salamanca, Salamanca, Spain
⁶Clinic for Hematology, Oncology and Palliative Care Marien Hospital Düsseldorf, Dusseldorf, Germany
⁷Royal Adelaide Hospital, Adelaide, SA, Australia
⁸Royal Adelaide Hospital and SA Pathology, Adelaide, SA, Australia
⁹Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL
¹⁰Department of Hematology and Oncology, Hospital Universitario Vall d'Hebron, Barcelona, Spain
¹¹Kero's Therapeutics, Lexington

4592

Development and Validation of a Biopsy-Free Scoring System for Screening Myelodysplastic Syndrome (MDS) and Associated Diseases in Cytopenic Patients

Sirilak Sutthinont¹^*, Nisa Makkruasi, MD²^*, Anothai Chintabanyat, M.D.³^*, Thanawat Rattanathammethee, M.D.⁴^*, Ponlapat Rojnuckarin, MD^5,6, Wiroj Jiamjarasrangsi, MD¹^* and Chantana Polprasert, MD^5,7^*

¹Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn Universityand King Chulalongkorn Memorial Hospital, Bangkok, Thailand
²Division of Hematology, Faculty of Medicine, Srinakharinwirot University, Nakhon Nayok, Thailand
³Division of Hematology, Department of Medicine, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand
⁴Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
⁵Division of Hematology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand
⁶Center of Excellence in Translational Hematology, Chulalongkorn University, Bangkok, Thailand
⁷Center of Excellence in Translational Hematology, Faculty of Medicine, Chulalongkorn University, Bangkok, Bangkok, Thailand

4593

Predictors of Blast Transformation (BT) and Post-BT Survival in Chronic Myelomonocytic Leukemia (CMML)

Anuya A. Natu, MBBS¹^*, Clifford M. Csizmar, MD, PhD¹, Terra L. Lasho, PhD², Rashmi Kanagal-Shamanna, MD³, Sanam Loghavi, MD⁴, Alexandre Bazinet, MD⁵^*, Kelly S. Chien, MD⁶, Danielle Hammond, MD⁷, Christy Finke, BS¹^*, Aref Al-Kali, MD¹, Hassan B Alkhateeb, MD¹^*, Naseema Gangat, MBBS¹, Abhishek A. Mangaonkar, MBBS², Antoine N. Saliba, MD¹, Ayalew Tefferi, MD¹, Guillermo Garcia-Manero, MD⁷, Hagop Kantarjian, MD⁷, Guillermo Montalban-Bravo, MD⁷ and Mrinal M. Patnaik, MD, MBBS¹

¹Division of Hematology, Mayo Clinic, Rochester, MN
²Mayo Clinic, Rochester, MN
³Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
⁴Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
⁵Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston
⁶Department of Leukemia, MD Anderson, Houston, TX
⁷Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

4594

TP53-Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors

Kevin Hung, MBBS, FRACP, FRCPA¹, Aref Al-Kali, MD², Carla Toop, PhD¹^*, Mrinal M. Patnaik, MD, MBBS², Zoe Price, BSc (Hons)³^*, Taxiarchis Kourelis, MD², Daniel Thomas, MBBS, PhD^1,3,4^*, Morie A. Gertz, MD², Hossein Anani⁴^*, Wilson I. Gonsalves, MD⁵, Chung Hoow Kok, PhD, BSc⁶, Ayalew Tefferi, MD², Devendra Hiwase, MD, MBBS, PhD, FRACP, FRCPA^1,3,4 and Mithun V Shah, M.D., Ph.D.²

¹Department of Haematology, Central Adelaide Local Health Network, Adelaide, SA, Australia
²Division of Hematology, Mayo Clinic, Rochester, MN
³South Australian Health and Medical Research Institute, Adelaide, SA, Australia
⁴Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia
⁵Division of Hematology, Mayo School of Graduate Medical Education, Rochester, MN
⁶Centre for Cancer Biology and SA Pathology, Adelaide, Australia

4595

R289, a Dual Irak 1/4 Inhibitor, in Patients with Relapsed/Refractory (R/R) Lower-Risk Myelodysplastic Syndrome (LR-MDS): Initial Results from a Phase 1b Study

Guillermo Garcia-Manero, MD¹, Yazan F Madanat, MD², Mikkael A. Sekeres, MD³, Hetty E. Carraway, MD, MBA⁴, Mike Cusnir, MD⁵, James McCloskey, MD⁶, Kiran Naqvi, MD, MPH⁷, Gary J. Schiller, MD⁸, Lucy Yan, MD, PhD⁹^*, Toufigh Gordi, PhD, MBA⁹^*, Lisa Rojkjaer, MD¹⁰ and Lewis R. Silverman, MD¹¹

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX
³Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
⁴Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
⁵Mount Sinai Comprehensive Cancer Ctr., Miami Beach, FL
⁶John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ
⁷Department of Medicine, Division of Hematology Oncology, Chao Family Comprehensive Cancer Center,, University of California Irvine Health, Orange, California, USA, Orange, CA
⁸David Geffen School of Medicine, UCLA, Los Angeles, CA
⁹Rigel Pharmaceuticals, Inc., South San Francisco, CA
¹⁰Rigel, Rancho Santa Fe, CA
¹¹Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY

4596

Pathogenic Germline Variants in the DNA Damage Repair Pathway Are Enriched in Patients with Hematologic Malignancies with Prior Exposure to Cytotoxic Therapies Compared to Patients with Multiple Cancers without Prior Exposure

Devendra Hiwase, MD, MBBS, PhD, FRACP, FRCPA^1,2,3, Zoe Price, BSc (Hons)¹^*, Chung How Kok, BSc, PhD^4,5^*, Monika Kutyna, PhD^1,3^*, Deepak Singhal, MBBS, MD, FRACP, FRCPA³^*, Naranie Shanmuganathan, MBBS, PhD, FRACP, FRCPA³, Lesley Rawlings⁴^*, David M Ross, MD, PhD, FRACP, FRCPA^3,6^*, David T Yeung, MBBS, PhD, BSc, FRACP, FRCPA^1,2,3, Anna Brown, PhD^4,5^*, Christopher N. Hahn, PhD^4,5^*, Lucy A. Godley, MD, PhD⁷, Caner Saygin, MD⁸ and Hamish S Scott, PhD^4,5

¹South Australian Health and Medical Research Institute, Adelaide, SA, Australia
²University of Adelaide, Adelaide, SA, Australia
³Department of Haematology, Central Adelaide Local Health Network, Adelaide, SA, Australia
⁴SA Pathology, Adelaide, SA, Australia
⁵University of South Australia, Adelaide, SA, Australia
⁶Flinders University, Adelaide, Australia
⁷Northwestern University, Chicago, IL
⁸University of Chicago, Chicago, IL

4597

Association between Smoking Intensity, Genetic Mutations, and Disease Progression in Myelodysplastic Syndromes

Sangeetha Venugopal, MD, MS¹, Michael Otterstatter, PhD²^*, Amy E. DeZern, MD³, Matthew J. Walter, MD⁴, James M. Foran, MD⁵, Rafael Bejar, MD, PhD⁶, Tareq Al Baghdadi, MD⁷^*, H. Joachim Deeg, MD⁸, Rami S. Komrokji, MD⁹, Gregory A Abel, MD, MPH¹⁰, R. Coleman Lindsley, MD¹⁰, Jane Jijun Liu¹¹^*, Yazan F Madanat, MD¹², Lynn C. Moscinski, MD¹³, Wael Saber, MD, MS¹⁴, Jennifer Vidrine¹⁵^*, Damon J. Vidrine¹⁵^*, Ling Zhang, MD¹⁶, Christine Borchert, BSc²^*, Seth Sherman, PhD²^*, Nancy DiFronzo, PhD¹⁷^*, Nancy Gillis, PhD¹⁸ and Mikkael A. Sekeres, MD¹

¹Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL
²The Emmes Company, LLC, Rockville, MD
³Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
⁴Washington University In St. Louis, Saint Louis, MO
⁵Division of Hematology & Medical Oncology, Mayo Clinic, Jacksonville, FL
⁶Aptose Biosciences, La Jolla, CA
⁷IHA Hematology Oncology, Ypsilanti, MI
⁸Fred Hutchinson Cancer Research Center, Seattle, WA
⁹Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
¹⁰Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
¹¹Illinois CancerCare, Peoria, IL
¹²Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX
¹³Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
¹⁴Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI
¹⁵Moffitt Cancer Center, Tampa, FL
¹⁶Department of Pathology and Laboratory Medicine, H. Lee Moffitt Cancer and Research Institute, Tampa, FL
¹⁷Division of Blood Diseases & Resources, The National Heart, Lung, and Blood Institute, Bethesda, MD
¹⁸Department of Cancer Epidemiology, Moffitt Cancer Center and Research Institute, Tampa, FL

4598

Impact of Frailty in a Prospective Cohort of Patients with MDS Treated with Hypomethylating Agents

James T England, MD, MSc, FRCPC¹, Liying Zhang, PhD²^*, Karen Yee, MD, FRCPC³^*, Michelle Geddes, MD⁴, Nancy Zhu, MD, FRCPC⁵^*, April Shamy, MD⁶, Heather A Leitch, MD, PhD⁷, Mitchell Sabloff, MSc, MD, FRCPC⁸, Grace Christou, MD, MSc, FRCPC⁹^*, Brett L. Houston, MD, PhD^10,11, Brian Leber, MD¹², Dina Khalaf, MSc, MBBS¹³, Eve St-Hilaire, MD, FRCP¹⁴^*, Nicholas Finn, BSc, MD¹⁵^*, Thomas J. Nevill, MD, FRCPC¹⁶, Amy Trottier, MD, MSc, FRCPC¹⁷, John M. Storring, MDCM, FRCPC¹⁸, Mohamed Elemary, MD, MSc, PhD¹⁹^*, Robert Delage, MD, MSc²⁰ and Rena Buckstein, MD, FRCPC¹

¹Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
²Sunnybrook Health Sciences Centre, Toronto, ON, Canada
³Princess Margaret Cancer Centre / University Health Network, Toronto, ON, Canada
⁴Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada
⁵Clinical Assistant Professor Division of Hematology, Department of Medicine, University of Alberta, Edmonton, AB, Canada
⁶Jewish General Hospital, McGill University, Montreal, QC, CAN
⁷Hematology, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada
⁸Ottawa Hospital Research Institute, Ottawa, ON, Canada
⁹Division of Hematology, The Ottawa Hospital, Ottawa, ON, Canada
¹⁰Cancercare Manitoba, Winnipeg, MB, CAN
¹¹University of Manitoba, Winnipeg, MB, CAN
¹²Division of Hematology, Juravinski Cancer Center, Hamilton, ON, Canada
¹³Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada
¹⁴Hematology/Oncology, Dr. Georges-L-Dumont University Centre, Moncton, NB, CAN
¹⁵Hematology/oncology, Dr. Georges-L-Dumont University Centre, Moncton, CAN
¹⁶Department of Medicine, Division of Hematology, University of British Columbia, Leukemia Bone Marrow Transplant Program of British Columbia and Vancouver General Hospital, Vancouver, BC, Canada, Vancouver, BC, CAN
¹⁷Hematology, Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada
¹⁸McGill University Health Centre, Montreal, QC, Canada
¹⁹Provincial Hematology and Blood and Marrow Transplant Program, Saskatchewan Cancer Agency, University of Saskatchewan, Saskatoon, SK, Canada
²⁰Integrated Cancer Center, CHU de Québec, Laval University, Quebec, QC, Canada

4599

Comparison of Clinicopathological Features of Patients with Two Spliceosome Gene Co-Mutations

Amy Song¹^*, Richard Shao²^*, Lynn C. Moscinski, MD³, Julie Li, MD³^*, Mohammad Omar Hussaini, MD⁴^*, Le Wang, MD, PhD⁵ and Hailing Zhang, MD³^*

¹Department of Internal Medicine, Columbia University Irving Medical Center, Princeton, NJ
²The University of Central Florida College of Medicine, Orlando, FL
³Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
⁴Department of Pathology and Laboratory Medicine, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
⁵Guthrie Clinic Cancer Center Robert Packer Hospital, Sayre, PA

4600

Olutasidenib Alone or in Combination with Azacitidine in Patients with mIDH1 Myelodysplastic Syndromes/Neoplasms: Final 5-Year Data

Jorge E. Cortes, MD¹, Justin M. Watts, MD², Eunice S. Wang, MD³, Jay Yang, MD⁴, Shira N. Dinner, MD⁵, Maria R. Baer, MD⁶, Gail J. Roboz, MD⁷ and William B. Donnellan, MD⁸

¹Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA
²Sylvester Cancer Center, University of Miami Miller School of Medicine, Miami, FL
³Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
⁴Department of Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, MI
⁵Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
⁶Department of Medicine, University of Maryland School of Medicine, Baltimore, MD
⁷Division of Hematology and Medical Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY
⁸Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN

4601

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome

Ian M. Bouligny, MD¹, Guillermo Montalban-Bravo, MD¹, Koji Sasaki, MD¹, Naval Daver, MD², Elias Jabbour, MD¹, Yesid Alvarado Valero, MD¹, Courtney D. DiNardo, MD, MSc³, Farhad Ravandi, MBBS⁴, Gautam Borthakur, MD⁵, Prithviraj Bose, MD⁶, Naveen Pemmaraju, MD⁷, Steven M. Kornblau, MD¹, Tapan M. Kadia, MD¹, Lucia Masarova, MD¹, Koichi Takahashi, MD, PhD⁸, Michael Andreeff, MD, PhD⁵, Alexandre Bazinet, MD¹^*, Hui Yang, PhD, MD¹, Rashmi Kanagal-Shamanna, MD⁹, Chitra Hosing, MD¹⁰, Sherry Pierce, BSN, BA¹^*, Meghan Anne Meyer, BSN, RN¹^*, Xuelin Huang, PhD¹¹^* and Guillermo Garcia-Manero, MD¹

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²MD Anderson Cancer Center, Houston, TX
³Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX
⁴Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX
⁵Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁶The University of Texas MD Anderson Cancer Center, Houston, TX
⁷Department of Leukemia, The University of Texas MD Anderson Cancer Center, Bellaire, TX
⁸Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
⁹Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
¹⁰Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
¹¹Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX

4602

A Retrospective Cohort Study Evaluating Outcomes of Higher Risk MDS Treated with Hypomethylating Agents with or without Venetoclax Using International Working Group 2023 Response Criteria

Mihir Shukla, MD¹, Chinyere Okpara, MS²^*, Elaine Xiang, PharmD³, Maher Abdul Hay, MD⁴, Shella Saint Fleur-Lominy, MD, PhD⁵ and Jun Han Choi, MD⁶

¹Perlmutter Cancer Center, New York University Grossman School of Medicine/NYU Langone Health, New York, NY
²Department of Surgery, NYU Grossman Long Island School of Medicine, Mineola, NY
³NYU Langone Health, New York, NY
⁴Perlmutter Cancer Center, NYU Langone Health, New York, NY
⁵NYU Perlmutter Cancer Center, New York University Grossman School of Medicine, New York, NY
⁶NYU Langone, New York, NY

4603

Azacitidine Versus Decitabine for the Treatment of Myelodysplastic Syndrome: A Propensity Score-Matched Retrospective Cohort Study Using Trinetx

Shanawar Waris, MD¹^*, Adnan Saifuddin, MD¹^*, Yashan Thakkar, BS²^*, Gary Monroe, DO¹^*, Zainab Fatima, MD³^*, Carl Shultz, DO³^*, Danish Safi, MD³ and Salah Ud Din Safi, MD⁴^*

¹Department of Internal Medicine, West Virginia University School of Medicine, Morgantown, WV
²West Virginia University School of Medicine, Morgantown, WV
³Department of Medical Oncology, West Virginia University Cancer Institute, Morgantown, WV
⁴West Virginia University Cancer Institute, Morgantown, WV

4604

Impact of Mutational Landscape and CD47 Levels in the Magrolimab + Azacitidine Vs Placebo + Azacitidine Trial in Patients with Untreated Higher Risk Myelodysplastic Syndrome

Lisa D.S. Johnson¹^* and Yajia Zhang, PhD²^*

¹Biomarker Sciences and Diagnostics, Gilead Sciences Inc., Foster City, CA
²Clinical Bioinformatics and Exploratory Analysis, Gilead Sciences Inc., Foster City, CA

4605

Appropriate Timing of Allogeneic Bone Marrow Transplant in Patients with Myelodysplastic Syndrome

Yanal Alnimer, MD, MPH¹^*, Reinhold Munker, MD², Ayman Qasrawi, MD³, Gregory Monohan⁴^*, Chait Iragavarapu³^* and Fevzi Yalniz, MD²^*

¹University of Kentucky, Tappahannock, VA
²Department of Hematology, University of Kentucky, Lexington, KY
³University of Kentucky, Lexington, KY
⁴University of Kentucky, Lexington

4605.1

Targeting the Myelodysplasia (MDS) Inflammasome with the Oral Wnt/β-Catenin Pathway Inhibitor, ES-3000 in Combination with Oral Decitabine/Cedazuridine (ASTX727) an Australasian Leukaemia and Lymphoma Group Trial (ALLG MDS05/D1)

Anoop K Enjeti, MBBS, FRCPA, MD, MRCP^1,2,3, Suthanthirakannan Ramamoorthy, MBBS FRACP⁴^*, Devendra Hiwase, MD, MBBS, PhD, FRACP, FRCPA⁵, Asma Ashraf, FRACP, MBBS, FRCPA⁶, Belinda E Butcher, BSc(Hons), MBiostat, PhD, CMPP AStat⁷^*, Sushma Kollipara⁸^*, Carolyn S. Grove, MBBS, FRACP, FRCPA, PhD^9,10, Andrew H Wei, MBBS, PhD, FRACP, FRCPA^11,12 and Jake Shortt¹³

¹Department of Haematology, Calvary Mater Hospital, Waratah, NSW, Australia
²Precision Medicine Research Program, Hunter Medical Research Institute, NSW, SA, Australia
³School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, Australia
⁴Haematology dept., Royal Darwin Hospital, Darwin, Australia
⁵Royal Adelaide Hospital, Adelaide, SA, Australia
⁶Calvary Mater Hospital, Waratah, AUS
⁷University of NSW, Sydney, Australia
⁸Australasian Leukaemia and Lymphoma Group, Melbourne, Australia
⁹School of Pathology and Laboratory Medicine, University of Western Australia, Perth, Australia
¹⁰Sir Charles Gairdner Hospital, Nedlands, Australia
¹¹Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
¹²The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia
¹³Monash University and Monash Health, Melbourne, VIC, Australia

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH